386 related articles for article (PubMed ID: 25645973)
21. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
22. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
Yang Y; He X; Rojas M; Leung PSC; Gao L
Front Immunol; 2023; 14():1184252. PubMed ID: 37325634
[TBL] [Abstract][Full Text] [Related]
23. Primary biliary cirrhosis in the era of liver transplantation.
Raczyńska J; Habior A; Pączek L; Foroncewicz B; Pawełas A; Mucha K
Ann Transplant; 2014 Sep; 19():488-93. PubMed ID: 25262831
[TBL] [Abstract][Full Text] [Related]
24. [Primary biliary cirrhosis: therapeutic options].
Abenavoli L
Recenti Prog Med; 2009 Sep; 100(9):417-23. PubMed ID: 19886235
[TBL] [Abstract][Full Text] [Related]
25. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
[TBL] [Abstract][Full Text] [Related]
26. Serial quantitative liver function tests in patients with primary biliary cirrhosis: a prospective long-term study.
v Schönfeld J; Breuer N; Zotz RB; Beste M; Goebell H
Digestion; 1997; 58(4):396-401. PubMed ID: 9324169
[TBL] [Abstract][Full Text] [Related]
27. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
28. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
[TBL] [Abstract][Full Text] [Related]
31. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic acid for primary biliary cirrhosis.
Gong Y; Huang ZB; Christensen E; Gluud C
Cochrane Database Syst Rev; 2008 Jul; (3):CD000551. PubMed ID: 18677775
[TBL] [Abstract][Full Text] [Related]
33. The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense.
Van Den Bogaert E; Francque S; Pelckmans P; Michielsen P
Acta Gastroenterol Belg; 2003; 66(4):283-7. PubMed ID: 14989050
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
Stojakovic T; Putz-Bankuti C; Fauler G; Scharnagl H; Wagner M; Stadlbauer V; Gurakuqi G; Stauber RE; März W; Trauner M
Hepatology; 2007 Sep; 46(3):776-84. PubMed ID: 17668874
[TBL] [Abstract][Full Text] [Related]
35. The natural history of PBC: has it changed?
Lee YM; Kaplan MM
Semin Liver Dis; 2005 Aug; 25(3):321-6. PubMed ID: 16143947
[TBL] [Abstract][Full Text] [Related]
36. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
[TBL] [Abstract][Full Text] [Related]
37. Finding the cure for primary biliary cholangitis - Still waiting.
Tanaka A; Gershwin ME
Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
Nikolovska D; Vasilev P; Mikhova A
Vutr Boles; 2000; 32(1):25-7. PubMed ID: 11195193
[TBL] [Abstract][Full Text] [Related]
39. The timing of liver transplantation in primary biliary cirrhosis.
Angulo P; Dickson ER
Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):657-68. PubMed ID: 10976021
[TBL] [Abstract][Full Text] [Related]
40. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
